Cytek Biosciences share price today

(CTKB)

Cytek Biosciences share price is $6.56 & ₹556.45 as on 12 Dec 2024, 2.30 'hrs' IST

$6.56

▲

-0.17

(-2.53%)

Market is closed - opens 8 PM, 12 Dec 2024

View live Cytek Biosciences share price in Dollar and Rupees. Guide to invest in Cytek Biosciences from India. Also see the sentimental analysis on Indian investors investing in Cytek Biosciences. Get details on the Indian mutual funds that are investing in Cytek Biosciences. Get Analyst recommendations and forecasts along with all the Cytek Biosciences's financials.

Cytek Biosciences share price movements

$6.46
$6.76
$6.56
1.52%
Downside
Day's Volatility :4.44%
Upside
2.96%
$4.66
$9.87
$6.56
28.96%
Downside
52 Weeks Volatility :52.79%
Upside
33.54%

Cytek Biosciences Returns

Period	Cytek Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	41.98%	-7.2%	0.0%
6 Months	11.42%	-1.5%	0.0%
1 Year	-16.08%	8.4%	0.0%
3 Years	-62.98%	7.1%	-20.0%

Cytek Biosciences Key Statistics

in dollars & INR

Previous Close	$6.73
Open	$6.76
Today's High	$6.76
Today's Low	$6.46
Market Capitalization	$861.7M
Today's Volume	$607.0K
52 Week High	$9.87
52 Week Low	$4.66
Revenue TTM	$201.2M
EBITDA	$-15.2M
Earnings Per Share (EPS)	$-0.08
Profit Margin	-5.05%
Quarterly Earnings Growth YOY	0.66%
Return On Equity TTM	-2.54%

How to invest in Cytek Biosciences from India?

It is very easy for Indian residents to invest directly in Cytek Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cytek Biosciences stock in both rupees (INR) and dollars (USD). Search for Cytek Biosciences or CTKB on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cytek Biosciences or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cytek Biosciences shares which would translate to 0.129 fractional shares of Cytek Biosciences as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Cytek Biosciences

33%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for Cytek Biosciences on INDmoney from India has grown in the last 30 days as on Dec 12, 2024. 33% more investors are searching Cytek Biosciences in the last 30 days versus the previous period.

Global Institutional Holdings in Cytek Biosciences

BlackRock Inc
13.25%
Vanguard Group Inc
9.14%
Brown Capital Management, LLC
7.37%
Hillhouse Capital Advisors, Ltd.
5.17%
State Street Corp
3.24%
Geode Capital Management, LLC
2.07%

Analyst Recommendation on Cytek Biosciences

Buy

75%Buy

25%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Cytek Biosciences(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cytek Biosciences

What analysts predicted

Upside of 28.05%

Current:

$6.56

Target:

$8.40

Insights on Cytek Biosciences

Price Movement
In the last 7 days, CTKB stock has moved up by 0.6%
Increasing Revenue
Revenue is up for the last 3 quarters, 44.86M → 51.5M (in $), with an average increase of 6.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -10.43M → 941.0K (in $), with an average increase of 1208.8% per quarter
CTKB vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 63.2% return, outperforming this stock by 75.7%
CTKB vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 119.1% return, outperforming this stock by 183.0%
Price to Sales
ForCTKB every $1 of sales, investors are willing to pay $4.4, whereas for Boston Scientific Corp., the investors are paying $8.3 for every $1 of sales.

Cytek Biosciences Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$57.9M	-
Net Income	$-16.8M	-
Net Profit Margin	-29.07%	-

	FY20	Y/Y Change
Revenue	$92.8M	↑ 60.39%
Net Income	$19.4M	↓ 215.36%
Net Profit Margin	20.91%	↑ 49.98%

	FY21	Y/Y Change
Revenue	$128.0M	↑ 37.82%
Net Income	$4.4M	↓ 77.24%
Net Profit Margin	3.45%	↓ 17.46%

	FY22	Y/Y Change
Revenue	$164.0M	↑ 28.2%
Net Income	$2.6M	↓ 41.68%
Net Profit Margin	1.57%	↓ 1.88%

	FY23	Y/Y Change
Revenue	$193.0M	↑ 17.67%
Net Income	$-12.1M	↓ 571.58%
Net Profit Margin	-6.29%	↓ 7.86%

	Q2 FY23	Q/Q Change
Revenue	$49.7M	↑ 33.99%
Net Income	$-4.4M	↓ 35.54%
Net Profit Margin	-8.83%	↑ 9.52%

	Q3 FY23	Q/Q Change
Revenue	$48.0M	↓ 3.41%
Net Income	$-6.5M	↑ 47.13%
Net Profit Margin	-13.45%	↓ 4.62%

	Q4 FY23	Q/Q Change
Revenue	$58.2M	↑ 21.32%
Net Income	$5.5M	↓ 185.24%
Net Profit Margin	9.45%	↑ 22.9%

	Q1 FY24	Q/Q Change
Revenue	$44.9M	↓ 22.96%
Net Income	$-6.2M	↓ 212.1%
Net Profit Margin	-13.75%	↓ 23.2%

	Q2 FY24	Q/Q Change
Revenue	$46.6M	↑ 3.92%
Net Income	$-10.4M	↑ 69.14%
Net Profit Margin	-22.38%	↓ 8.63%

	Q3 FY24	Q/Q Change
Revenue	$51.5M	↑ 10.47%
Net Income	$941.0K	↓ 109.02%
Net Profit Margin	1.83%	↑ 24.21%

	FY19	Y/Y Change
Total Assets	$70.4M	-
Total Liabilities	$112.1M	-

	FY20	Y/Y Change
Total Assets	$220.0M	↑ 212.64%
Total Liabilities	$236.0M	↑ 110.6%

	FY21	Y/Y Change
Total Assets	$463.7M	↑ 110.79%
Total Liabilities	$56.9M	↓ 75.89%

	FY22	Y/Y Change
Total Assets	$519.5M	↑ 12.03%
Total Liabilities	$93.9M	↑ 65.08%

	FY23	Y/Y Change
Total Assets	$494.5M	↓ 4.82%
Total Liabilities	$101.4M	↑ 7.95%

	Q2 FY23	Q/Q Change
Total Assets	$525.1M	↑ 0.09%
Total Liabilities	$100.9M	↓ 0.24%

	Q3 FY23	Q/Q Change
Total Assets	$519.4M	↓ 1.07%
Total Liabilities	$103.9M	↑ 3.0%

	Q4 FY23	Q/Q Change
Total Assets	$497.7M	↓ 4.19%
Total Liabilities	$104.6M	↑ 0.67%

	Q1 FY24	Q/Q Change
Total Assets	$492.1M	↓ 1.13%
Total Liabilities	$99.5M	↓ 4.93%

	Q2 FY24	Q/Q Change
Total Assets	$483.7M	↓ 1.7%
Total Liabilities	$94.6M	↓ 4.88%

	Q3 FY24	Q/Q Change
Total Assets	$491.2M	↑ 1.55%
Total Liabilities	$105.8M	↑ 11.8%

	FY19	Y/Y Change
Operating Cash Flow	$-13.7M	-
Investing Cash Flow	$-973.0K	-
Financing Cash Flow	$93.0K	-

	FY20	Y/Y Change
Operating Cash Flow	$15.2M	↓ 210.25%
Investing Cash Flow	$-1.5M	↑ 58.99%
Financing Cash Flow	$122.6M	↑ 131735.48%

	FY21	Y/Y Change
Operating Cash Flow	$4.6M	↓ 69.45%
Investing Cash Flow	$-21.0M	↑ 1257.01%
Financing Cash Flow	$213.6M	↑ 74.18%

	FY22	Y/Y Change
Operating Cash Flow	$-12.2M	↓ 364.17%
Investing Cash Flow	$-55.9M	↑ 166.32%
Financing Cash Flow	$5.5M	↓ 97.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-2.9M	↓ 199.72%
Investing Cash Flow	$2.8M	↓ 101.65%
Financing Cash Flow	$216.0K	↑ 6.4%

Cytek Biosciences Technicals Summary

Sell

Neutral

Buy

Cytek Biosciences is currently in a neutral trading position according to technical analysis indicators.

Cytek Biosciences Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cytek Biosciences Inc	-5.87%	11.42%	-16.08%	-62.98%	-64.13%
Stryker Corporation	1.01%	11.56%	28.19%	47.14%	87.36%
Boston Scientific Corp.	1.94%	17.2%	59.7%	117.72%	99.56%
Edwards Lifesciences Corp.	10.03%	-16.29%	-2.43%	-39.22%	-6.29%
Abbott Laboratories	-1.11%	11.65%	7.69%	-15.05%	33.68%
Medtronic Plc	-5.31%	2.35%	2.05%	-25.94%	-27.03%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cytek Biosciences Inc	351.5	NA	NA	0.11	-0.03	-0.03	NA	2.97
Stryker Corporation	40.97	40.97	2.66	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.55	74.55	1.61	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	28.34	28.34	6.51	2.55	0.19	0.11	NA	16.18
Abbott Laboratories	35.11	35.11	2.23	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cytek Biosciences Inc	Buy	$861.7M	-64.13%	351.5	-5.05%
Stryker Corporation	Buy	$145.9B	87.36%	40.97	16.34%
Boston Scientific Corp.	Buy	$132.9B	99.56%	74.55	11.26%
Edwards Lifesciences Corp.	Buy	$43.3B	-6.29%	28.34	65.86%
Abbott Laboratories	Buy	$200.3B	33.68%	35.11	13.99%
Medtronic Plc	Buy	$110.6B	-27.03%	26.38	12.06%

About Cytek Biosciences

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.

Organization	Cytek Biosciences
Employees	645
CEO	Dr. Wenbin Jiang Ph.D.
Industry	Healthcare

Management People of Cytek Biosciences

Name	Title
Dr. Wenbin Jiang Ph.D.	President, CEO & Chairman of the Board
Dr. Ming Yan Ph.D.	CTO & Director
Ms. Valerie T. Barnett J.D.	Chief Legal Officer & Corporate Secretary
Dr. Allen B. Poirson Ph.D.	Senior Vice President of Business & Corporate Development
Mr. Patrik Sebastian Jeanmonod	Head of Corporate Development Analytics
Mr. William D. McCombe	Chief Financial Officer
Dr. Philippe Busque Ph.D.	Senior Vice President of Global Sales & Services

Important FAQs about investing in Cytek Biosciences from India :

What is Cytek Biosciences share price today?

Cytek Biosciences (CTKB) share price today is $6.56.

Can Indians buy Cytek Biosciences shares?

Yes, Indians can invest in the Cytek Biosciences (CTKB) from India.

With INDmoney, you can buy Cytek Biosciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cytek Biosciences at zero transaction cost.

How can I buy Cytek Biosciences shares from India?

It is very easy to buy Cytek Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cytek Biosciences be purchased?

Yes, you can buy fractional shares of Cytek Biosciences with INDmoney app.

What are the documents required to start investing in Cytek Biosciences stocks?

To start investing in Cytek Biosciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.